UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 15, 2010
MedAssets, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 001-33881 | | 51-0391128 |
| | | | | |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| | | | | |
100 North Point Center E, Suite 200,
Alpharetta, Georgia | | | | 30022 |
| | | | | |
(Address of principal
executive offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code: 678-323-2500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | |
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| | |
| Item 7.01 | | Regulation FD Disclosure. |
The Company is disclosing under Item 7.01 of this Current Report on Form 8-K information included as Exhibit 99.1. This information, some of which has not been previously reported (including revised disclosure regarding certain unaudited pro forma financial information), is derived from the Confidential Offering Memorandum, dated as of November 9, 2010, that is being circulated in connection with the previously disclosed private placement offering of senior notes due 2018. The results for periods of less than a full year are not necessarily indicative of the results to be expected for any other interim period or for a full year. Accordingly, investors and stockholders should not place undue reliance on the financial information and operating data.
The information furnished pursuant to, and incorporated by reference in, Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filing.
| | |
| Item 9.01 | | Financial Statements and Exhibits. |
(d) Exhibits
Number and Description
| | |
| 99.1 | | Excerpts from the Confidential Offering Memorandum, dated as of November 9, 2010. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | MedAssets, Inc.
| |
| November 15, 2010 | By: | /s/ L. Neil Hunn | |
| | | Name: | L. Neil Hunn | |
| | | Title: | Executive Vice President and Chief Financial Officer and President of Revenue Cycle Technology | |
| |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
| 99.1 | | Excerpts from the Confidential Offering Memorandum, dated as of November 9, 2010. |
